NanoViricides, Inc. (NASDAQ:NNVC)

BRIEF

published on 05/15/2024 at 12:35, 1 year 11 months ago

NanoViricides Reports Financial Update and Advancements in Clinical Trials

NanoViricides NV-387 Financial Report Clinical Trials Antiviral Treatment
PRESS RELEASE

published on 05/15/2024 at 12:30, 1 year 11 months ago

NanoViricides Has Filed its Quarterly Report
NanoViricides, Inc. reports advancing NV-387 to Phase II Clinical Trial for RSV infection treatment. Financial status and future plans discussed

NV-387 Phase II Clinical Trial NanoViricides Inc. RSV Infection Antiviral Nanomedicines
BRIEF

published on 05/14/2024 at 12:35, 1 year 11 months ago

NanoViricides Announces Breakthrough in RSV Treatment with NV-387

NanoViricides NV-387 Pharmaceutical Innovation RSV Treatment Antiviral Research
PRESS RELEASE

published on 05/14/2024 at 12:30, 1 year 11 months ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides, Inc. announces complete survival of animals lethally infected with RSV in lungs upon NV-387 oral treatment. Promising antiviral activity shown in study

NV-387 NanoViricides Inc. Antiviral Treatment RSV Infection Lung Infection
BRIEF

published on 05/08/2024 at 12:35, 1 year 11 months ago

NanoViricides Announces Promising Results with NV-387 in Potentially Treating Smallpox and Mpox

NanoViricides NV-387 Tecovirimat Smallpox Mpox
PRESS RELEASE

published on 05/08/2024 at 12:30, 1 year 11 months ago

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
NanoViricides reports NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox via inhalation and skin transmission. Study highlights efficacy in lethal animal models, supporting clinical development potential

NanoViricides NV-387 Clinical Development Orthopoxvirus Antiviral
BRIEF

published on 05/06/2024 at 12:35, 1 year 11 months ago

NanoViricides Reports Promising Results for NV-387 in Treating Influenza A

NanoViricides NV-387 Antiviral Drugs Influenza A H5N1 Bird Flu
PRESS RELEASE

published on 05/06/2024 at 12:30, 1 year 11 months ago

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
NanoViricides reports strong anti-influenza activity of NV-387, suggesting effectiveness against H5N1 bird flu virus. Results show superior performance to approved drugs. Further studies needed for confirmation

NanoViricides NV-387 Anti-influenza H5N1 Drug
BRIEF

published on 04/30/2024 at 12:35, 2 years ago

NanoViricides Announces Successful Completion of Phase I Clinical Trial for NV-387

NanoViricides NV-387 Phase I Clinical Trial Antiviral Treatment RSV Infection
PRESS RELEASE

published on 04/30/2024 at 12:30, 2 years ago

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
NanoViricides reports successful completion of Phase I Clinical Trial of NV-387, progresses towards Phase II discussion with physicians and experts for dosing protocol determination

NanoViricides NV-387 Phase I Clinical Trial Phase II Discussion Antiviral Drug

Published on 05/01/2026 at 18:00, 28 minutes ago

Star Copper to Present at the Emerging Growth Conference on May 7, 2026
Published on 05/01/2026 at 15:35, 2 hours 53 minutes ago

LNG Energy Group Announces Partial Revocation of Cease Trade Order and Proposed Private Placement
Published on 05/01/2026 at 14:00, 4 hours 28 minutes ago

CCL Industries Closing of ALT Technologies Acquisition
Published on 05/01/2026 at 14:00, 4 hours 28 minutes ago

Datavault AI and CyberCatch Announce Signing of Binding Letter of Intent for Datavault AI to Acquire CyberCatch to Accelerate AI-Driven, Quantum-Resistant Cyber Risk Mitigation Solutions
Published on 05/01/2026 at 13:01, 5 hours 27 minutes ago

BeMetals Announces Resumption of Trading on TSX Venture Exchange and Effective Date of Share Consolidation

View all ACCESSWIRE

Published on 05/01/2026 at 17:47, 40 minutes ago

Key Figures 30.04.2026
Published on 05/01/2026 at 17:45, 42 minutes ago

Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 1 hour 6 minutes ago

Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 05/01/2026 at 15:59, 2 hours 28 minutes ago

Shares Admitted to Trading and Total Voting Rights
Published on 05/01/2026 at 15:37, 2 hours 50 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc

View all EQS

Published on 04/30/2026 at 20:00, 22 hours 27 minutes ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 23 hours 12 minutes ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 23 hours 28 minutes ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 1 day ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News